@jennifer-carroll Thank you for taking the time to explain the nuances! Just to have clarity, this is how I interpret your answers:
- Needs to be in a peer-reviewed journal, complete and unmarked
- Needs to be consistent of Marketing Authorization
- Can be review papers, disease state papers, sub studies of phase 3 trials in line with the marketing authorization
- If used by sales, papers should not be used as detail aid, or combined with any detail aid, but can be discussed reactively and not distributed.
- Needs to respect the PAAB code, sections that you mentioned, although these pertain more to APSs, so I assume a lone-standing peer-reviewed paper is in alignmnet with this.
Thank you!!